Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.43% to $554.18 Friday, on what proved to be an all-around great trading ...

Regeneron Pharmaceuticals Inc. closed 54.89% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face ...

Guggenheim analyst Yatin Suneja lowered the firm’s price target on Regeneron (REGN) to $940 from $950 and keeps a Buy rating on the shares. The ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Buying $1000 In REGN: If an investor had bought $1000 of REGN stock 20 years ago, it would be worth $130,880.12 today based on a price of $638.70 for REGN at the time of writing.

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

The teen is the first student from Levittown's General Douglas MacArthur High School to be named a finalist in the ...

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...

Shares of Regeneron Pharmaceuticals Inc. slipped 4.06% to $634.14 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.16% to ...